Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.

Pfizer

Status and phase: Completed; Phase 2

Conditions: Female Sexual Dysfunction

Treatments: Drug: PF-00446687; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00479570

A8361015

Details and patient eligibility

About

The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on acute sexual arousal and sexual interest in post menopausal females, as well as examining the safety and toleration of the drug.

Enrollment: 23 patients

Sex: Female

Ages: 45 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women who have evidence of Female Sexual Arousal Disorder.
• Women who experience personal distress due to Female Sexual Dysfunction.
• Post menopausal women aged between 45 and 65 years.

Exclusion criteria

• Women whose sexual dysfunction is limited to certain types of stimulation, situation or specific partners.
• Women who experience pain with sexual intercourse or who have a sexual aversion disorder.
• Women suffering from female sexual dysfunction where the cause is treatable, for example inadequately controlled diabetes or thyroid dysfunction.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

23 participants in 2 patient groups, including a placebo group

Study period 1, 2 or 3

Experimental group

Treatment:

Drug: PF-00446687

Placebo Study period 1, 2 or 3

Placebo Comparator group

Treatment:

Drug: Placebo